老虎證券

BUZZ-MetaVia rises after experimental obesity drug shows promise in early-stage study

Reuters
04/15
BUZZ-MetaVia rises after experimental obesity drug shows promise in early-stage study

** Shares of drug developer MetaVia MTVA.O rise 17.9% to $2.17 premarket

** Co says its experimental obesity drug showed a maximum reduction of 6.3% in body weight in a 28-day, 36-patient portion of an early-stage trial

** The drug, DA-1726, on average reduced body weight by 4.3%

** Additionally, MTVA says DA-1726 showed waist circumference reduction of 1.6 inches on average, with a maximum reduction of 3.9 inches by day 33

** "We anticipate that greater weight loss may be seen in longer duration studies" - co

** In November, co changed its name to MetaVia from NeuroBo Pharmaceuticals

** Up to last close, stock had fallen 9.4% YTD

(Reporting by Puyaan Singh)

((Puyaan.Singh@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10